基于AI的组织病理学分析预测晚期黑色素瘤免疫检查点抑制剂反应并识别相关模式
该研究回顾性纳入荷兰11个中心2016至2023年接受一线抗PD1±抗CTLA4治疗的晚期皮肤黑色素瘤患者,利用14个基础模型结合注意力或聚类约束多实例学习分析治疗前转移灶H&E切片。最佳AI模型预测客观缓解率的AUROC为0.63,联合临床信息后提升至0.66,预测由免疫浸润、上皮样形态、梭形细胞形态和坏死等可解释组织学特征驱动。
要点
- AI分析治疗前转移灶H&E切片可预测晚期黑色素瘤ICI反应,最佳AUROC为0.63。
- AI联合临床信息后AUROC提升至0.66且校准改善。
- 预测由免疫浸润和上皮样形态(反应)及梭形细胞形态和坏死(非反应)驱动。
核心结论
- 基于AI的治疗前转移灶组织病理学分析可利用可解释的组织学特征预测晚期黑色素瘤ICI结局。
- AI分析联合临床信息后预测性能进一步提升。
研究设计与样本
- 回顾性研究,利用前瞻性收集的登记数据识别2016至2023年荷兰11个中心接受一线抗PD1±抗CTLA4治疗的晚期皮肤黑色素瘤患者。
- 收集来自30个病理实验室的治疗前转移灶H&E切片,使用14个基础模型结合注意力或聚类约束多实例学习分析。
- 主要结局为最佳总体缓解率(RECIST 1.1),通过留一医院交叉验证评估。
- 1935例患者中1177例有治疗前转移灶标本,35.3%接受抗PD1+抗CTLA4联合治疗。
主要发现
- 总体客观缓解率为56.7%(667/1177)。
- 最佳AI模型AUROC为0.63(95%CI:0.60-0.66),风险被高估。
- AI联合临床信息后AUROC提升至0.66(95%CI:0.63-0.69),校准改善。
- 预测由免疫浸润和上皮样形态驱动反应,由梭形细胞形态和坏死驱动非反应。
临床怎么用
- AI分析治疗前转移灶H&E切片可作为预测晚期黑色素瘤ICI反应的辅助工具。
- 结合临床信息(如WHO体能状态、肝转移、LDH、ICI类型、AJCC分期、脑转移)可提升预测性能。
- 组织学特征(免疫浸润、细胞形态、坏死)可解释AI预测,辅助临床解读。
局限性
- 回顾性研究设计。
- AI模型预测性能中等(AUROC 0.63-0.66)且存在风险高估。
- 仅35.3%患者接受联合治疗,多数为单药治疗,结果可能受治疗类型影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Readily available predictive biomarkers for immune checkpoint inhibitor (ICI) response in advanced melanoma are limited. This study evaluates the predictive value of AI-based histopathology analysis. METHODS: Patients with advanced cutaneous melanoma treated with first-line anti-PD1 ±anti-CTLA4 between 2016 and 2023 across 11 Dutch centers were retrospectively identified using prospectively collected registry data. Pre-treatment H&E-stained metastatic slides were collected from 30 pathology labs and analyzed using 14 foundation models combined with attention-based or clustering-constrained multiple-instance learning. Primary outcome was best overall response (ORR) (RECIST 1.1) assessed through leave-one-hospital-out cross-validation. Response probabilities were added to a clinical model built with AIC-based backward selection (including WHO performance status, liver metastases, LDH, ICI-type, AJCC stage, brain metastases). Feature embedding clusters were labelled by three pathologists blinded to outcomes to assess histology driving predictions. RESULTS: Of 1935 patients, 1177 had a pre-treatment metastatic specimen available, most commonly lymph node or skin/soft tissue; 35.3% was treated with anti-PD1 +anti-CTLA4 combination therapy. ORR was 56.7% (n = 667/1177). The best AI-based model achieved an AUROC of 0.63 (95% CI:0.60-0.66) with overestimated risk. Combining the AI-based analysis with clinical information increased AUROC to 0.66 (95% CI:0.63-0.69) with improved calibration. Model predictions were driven by immune infiltration and epithelioid morphology for response, and by spindle-cell morphology, and necrosis for non-response. CONCLUSION: AI-based analysis of diagnostic pre-treatment metastatic melanoma samples predicts ICI outcomes by using explainable histological features, such as immune infiltration, cell morphology, and necrosis. The predictive performance of the AI-based analysis improves further upon addition of clinical information.
引用
- Schuiveling M, van Duin IAJ, Ter Maat LS, et al. AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response. Eur J Cancer. 2026. PMID: 42208280. doi:10.1016/j.ejca.2026.116831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。